Abstract
Objective: To investigate the effect of cucurmosin (CUS) on proliferation inhibition in the human pancreatic cancer cell line SW-1990 in vitro and in vivo.
Methods: 1. MTT assay was used to analyse the proliferation inhibition of CUS in SW-1990 cells compared with gemcitabine (GEM) in vitro. 2. We established an NOD-SCID mice orthotopic transplantation model and estimated the proliferation inhibition effect of CUS in SW-1990 cells in vivo. 3. Western blot was used to determine the protein expressions of Caspase 3, Bcl-2, Caspase 9, PI3K, Akt, mTOR, P70S6k, and 4E-BP1 after CUS intervention.
Results: 1. CUS inhibited the proliferation of pancreatic cancer cells and induced apoptosis in CUS dose- and time-dependent manners. 2. NOD-SCID mice models were established successfully, and the tumour proliferation inhibition rates of these models increased compared with the control group. 3. CUS inhibited all of the examined proteins in the PI3K/Akt/mTOR signalling pathway and induced active fragments of Caspase 3 and Caspase 9.
Conclusion: 1. CUS can inhibit the growth of SW-1990 cells in vitro and in vivo. 2. CUS can induce apoptosis in SW-1990 cells to inhibit cell growth.
Keywords: Pancreatic cancer, cucurmosin, proliferation inhibition, apoptosis.
Anti-Cancer Agents in Medicinal Chemistry
Title:Cucurmosin Kills Human Pancreatic Cancer SW-1990 Cells in vitro and in vivo
Volume: 13 Issue: 6
Author(s): Jieming Xie, Congfei Wang, Aiqin Yang, Baoming Zhang, Qiang Yin, Heguang Huang and Minghuang Chen
Affiliation:
Keywords: Pancreatic cancer, cucurmosin, proliferation inhibition, apoptosis.
Abstract: Objective: To investigate the effect of cucurmosin (CUS) on proliferation inhibition in the human pancreatic cancer cell line SW-1990 in vitro and in vivo.
Methods: 1. MTT assay was used to analyse the proliferation inhibition of CUS in SW-1990 cells compared with gemcitabine (GEM) in vitro. 2. We established an NOD-SCID mice orthotopic transplantation model and estimated the proliferation inhibition effect of CUS in SW-1990 cells in vivo. 3. Western blot was used to determine the protein expressions of Caspase 3, Bcl-2, Caspase 9, PI3K, Akt, mTOR, P70S6k, and 4E-BP1 after CUS intervention.
Results: 1. CUS inhibited the proliferation of pancreatic cancer cells and induced apoptosis in CUS dose- and time-dependent manners. 2. NOD-SCID mice models were established successfully, and the tumour proliferation inhibition rates of these models increased compared with the control group. 3. CUS inhibited all of the examined proteins in the PI3K/Akt/mTOR signalling pathway and induced active fragments of Caspase 3 and Caspase 9.
Conclusion: 1. CUS can inhibit the growth of SW-1990 cells in vitro and in vivo. 2. CUS can induce apoptosis in SW-1990 cells to inhibit cell growth.
Export Options
About this article
Cite this article as:
Xie Jieming, Wang Congfei, Yang Aiqin, Zhang Baoming, Yin Qiang, Huang Heguang and Chen Minghuang, Cucurmosin Kills Human Pancreatic Cancer SW-1990 Cells in vitro and in vivo, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (6) . https://dx.doi.org/10.2174/18715206113139990109
DOI https://dx.doi.org/10.2174/18715206113139990109 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial: Exploring Lipid-related Treatment Options for the Treatment of NASH
Current Vascular Pharmacology Multimodal Optical, X-Ray CT, and SPECT Imaging of a Mouse Model of Breast Cancer Lung Metastasis
Current Molecular Medicine Stem Cell Pharmacogenomics
Current Topics in Medicinal Chemistry Mesenchymal Stem Cells Induced In Vitro Generated Regulatory-T Cells: Potential Soldiers of Transplantation Biology
Current Biotechnology ZnO Nanoparticles Catalyst in the Synthesis of Bioactive Fused Pyrimidines as Anti-breast Cancer Agents Targeting VEGFR-2
Medicinal Chemistry Circulating Tumor Stem Cells as Biomarkers for Cancer Progression
Recent Patents on Biomarkers An Overview on Keratinocyte Growth Factor: From the Molecular Properties to Clinical Applications
Protein & Peptide Letters MHC Class I TCR Engineered Anti-Tumor CD4 T Cells: Implications For Cancer Immunotherapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Benzofuran Small Molecules as Potential Inhibitors of Human Protein Kinases. A Review
Current Pharmaceutical Design Personalized Medicine for Glioblastoma: Current Challenges and Future Opportunities
Current Molecular Medicine Meet Our Editorial Board Member
Current Biomarkers (Discontinued) Interception of Cocaine by Enzyme or Antibody Delivered with Viral Gene Transfer: A Novel Strategy for Preventing Relapse in Recovering Drug Users
CNS & Neurological Disorders - Drug Targets p53-Induced Apoptosis and Inhibitors of p53
Current Medicinal Chemistry The Application of Single Nucleotide Polymorphism Microarrays in Cancer Research
Current Genomics Editorial (Thematic Issue: Global Trends for Nanotechnological Approaches in Various Health Issues - Part 1)
Current Drug Metabolism Novel Therapeutic Approaches to Regulate Human Dihydrofolate Reductase Activity and Expression
Current Enzyme Inhibition Toward Small-Molecule Inhibition of Protein–Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions
Current Topics in Medicinal Chemistry Anti-Angiogenic and Anti-Inflammatory Effects of Statins: Relevance to Anti-Cancer Therapy
Current Cancer Drug Targets Hematoma Expansion: Clinical and Molecular Predictors and Corresponding Pharmacological Treatment
Current Drug Targets Current Concepts on the Management of Chordoma
Current Drug Therapy